Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07594587
A Study of Ruxolitinib in Patients With Graft-Versus Host Disease
Sponsor: Novartis Pharmaceuticals
View on ClinicalTrials.gov
Summary
This study aims to evaluate the safety and effectiveness of Jakavi® (ruxolitinib) in patients with acute graft-versus host disease (GVHD) and chronic GVHD in clinical practice.
Official title: Post-marketing Database Study in Patients With Graft-Versus Host Disease for JAKAVI Tablets
Key Details
Gender
All
Age Range
0 Years - Any
Study Type
OBSERVATIONAL
Enrollment
395
Start Date
2026-05-11
Completion Date
2030-05-15
Last Updated
2026-06-08
Healthy Volunteers
No
Conditions
Locations (1)
Novartis
Tokyo, Japan